Pharmaceutical products; requiring manufacturers to publish certain list of ingredients; providing administrative, civil, and criminal penalties and remedies. Effective date.
SB 941 would create a new set of disclosure and enforcement requirements for manufacturers of pharmaceutical products in Oklahoma. It defines “pharmaceutical product” broadly to include prescription drugs, over-the-counter medications, vaccines, and products intended for research purposes, and it defines “ingredient” to include active and inactive components, biological materials, synthetic materials, and additives. Manufacturers would be required to publish a complete, detailed ingredient list for each product, including chemical and common names, source information for biological materials, the purpose of each ingredient, and quantities or concentrations. For products using mRNA or other gene-based technology, the bill would require disclosure of nucleic acid sequences, sources, and delivery mechanisms such as lipid nanoparticles.
The bill also requires ingredient information to be submitted to the State Board of Pharmacy, posted on a manufacturer-maintained public website, and included in labeling and marketing materials. It states that disclosure obligations remain in place even during a declared national emergency and that individual rights may not be suspended or infringed during such emergencies. The measure further directs the State Board of Pharmacy to create a complaint reporting system and forward reports to the Legislature, while reserving exclusive rulemaking authority to the Legislature and making the act controlling over conflicting laws.
If enacted, SB 941 would significantly expand state-level transparency requirements for drug and vaccine manufacturers and create new compliance obligations affecting product labeling, public disclosures, and reporting to state regulators. It would also add a new enforcement framework under Title 63 of the Oklahoma Statutes, including administrative penalties, civil remedies, injunctive relief, and criminal liability for repeated or intentional misrepresentation or omission. The bill would apply broadly to manufacturers, distributors, and sellers of noncompliant products in Oklahoma.
The bill’s enforcement provisions are substantial. Noncompliance could trigger fines up to $50,000 per violation per product, with escalating penalties for repeat violations, suspension or revocation of distribution rights, and possible misdemeanor charges carrying up to one year in jail for repeated or intentional omissions or misrepresentations. It also creates a private right of action, including class actions, for individuals or groups harmed by noncompliance, and allows the state to seek injunctions. Whistleblowers would receive retaliation protections and could receive a share of collected fines.
No committee transcript or vote record is available, so there is no documented debate or recorded sentiment from hearings. Based on the bill text alone, the measure appears strongly regulatory and enforcement-oriented, with an emphasis on transparency and individual rights. The main likely point of contention is the breadth and intrusiveness of the disclosure mandate, especially for proprietary formulations, research products, and gene-based technologies, as well as the bill’s unusually severe penalties and its assertion of legislative control over rulemaking and emergency-related restrictions.
SB 941 would add new sections to Title 63 of the Oklahoma Statutes establishing mandatory ingredient disclosure rules for pharmaceutical manufacturers, including public posting, submission to the State Board of Pharmacy, and inclusion in labeling and marketing. It would create new administrative, civil, and criminal penalties for noncompliance, authorize private lawsuits and class actions, provide whistleblower protections and rewards, and require the Board to establish a complaint reporting system. The bill also preempts conflicting laws and reserves implementation rulemaking to the Legislature, while taking effect January 1, 2026.
There are no committee transcripts or votes in the provided record, so no direct legislative sentiment can be measured. From the bill language, the measure is framed as a transparency and accountability bill, suggesting support from sponsors who favor disclosure and consumer access to ingredient information. At the same time, the breadth of the requirements and penalties suggests it could draw significant opposition from pharmaceutical manufacturers, health care stakeholders, and others concerned about trade secrets, regulatory burden, and the treatment of vaccines and gene-based products.
The most notable points of contention are likely the bill’s broad definition of pharmaceutical products, which includes vaccines and research products, and its requirement to disclose detailed ingredient, source, and quantity information for all components. Industry stakeholders may object to public disclosure of proprietary or sensitive formulation data, while supporters may argue that full transparency is necessary for informed consent and public accountability. Additional controversy may arise from the bill’s emergency-related language, its severe fines and criminal penalties, the private right of action and class action provisions, and the Legislature’s exclusive rulemaking authority, which limits agency discretion.